MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) to begin marketing INFUSE® Bone Graft for certain oral maxillofacial and dental regenerative bone grafting procedures. This will be the third Pre-Market Approval (PMA) Application receiving FDA approval since 2002 for the INFUSE Bone Graft technology.
